Lercanidipine in diabetic patients with renal failure;Lercanidipino en pacientes diabéticos con insuficiencia renal

Nefrologia

Volumn 24, Issue 4, 2004, Pages 338-343

  Robles, N R ^a   Pastor, L ^b   Manjon M ^b   Ocon J ^b   Gomez Campdera F ^b   Herrera, J ^b   Villatoro, J ^b   Calls, J ^b   Torrijos, J ^b   Rodriguez Villareal I ^b   Rodriguez Martinez M A ^b   Mendez M L ^b   Morey, A ^b   Martinez Fernandez J ^b   Marco, J ^b   Liebana A ^b   Rincon B ^b   Tornero, F ^a  

^a HOSPITAL INFANTA CRISTINA   (Spain)

^b NONE

Author keywords

Chronic renal failure; Diabetes mellitus; Lercanidipine

Indexed keywords

CREATININE; LERCANIDIPINE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LABORATORY TEST; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; SIDE EFFECT; TREATMENT OUTCOME;

AGED; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; CREATININE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DIHYDROPYRIDINES; EDEMA; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROTEINURIA; TREATMENT OUTCOME;

EID: 4544253841     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. American Diabetes Association. Treatment of hipertension in adults with diabetes. Diabetes Care 26 (Supl. 1): S80-S82, 2002.
2. United States Renal Data System, USRDS 1999 Annual Data Report. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Am J Kisney Dis 34: 41-151, 1999.
3. Spanish Nephrology Association Registry Committee and Regional Registries. 1997 Spanish Nephrology Association (Sociedad Española de Nefrología) Report on Dialysis and Trasplantation. Nephrol Dial Transplant 14: 2841-2845, 1999.
4. Parving HH, Andersen AR, Smidt UM, Svedesn PA: Early aggresive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet i: 1175-1179, 1983.
5. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD for the Collaborative Study Group, a clinical trial of an angiotensin converting enzyme inhibitor in the nephropathy of insulin-dependent diabetes mellitus. N Engl J Med 329: 1456-1462, 1993.
6. Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P: For the Irbesartan in patients with type 2 diabetes and microalbuminuria study group. N Engl J Med 345: 870-878, 2001.
7. Lewis E, Hunsickler LG, Clarke WR, Berl T, Pons MA, Lewis JB y cols.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851-860, 2001.
8. Brenner BM, Cooper ME, De Zeeuw D, Keane WF, Mitch WE, Parving HH y cols.: Effect of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869, 2001.
9. Barrios V, Navarro A, Esteras A, Luque M, Romero J, Tamargo J y cols.: Antihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. The ELYPSE study. Blood Pressure 11: 95-100, 2002.
10. Leonetti G, Magnani B, Pessina AC, Rappelli A, Trimarco B, Zanchetti A on behalf of the COHORT Study Croup: Tolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives. Am J Hypertens 15: 932-940, 2002.
11. DiGiorgio LA, Orlandini F, Malasoma P, Zappa A: A double-blind cross-over study of lercanidipine versus amlodipine in the treatment of mild-to-moderate essential hipertension. Curr Ther Res 60: 511-520, 1999.
12. Tobbe S, Epstein M: The use of calcium antagonists in the treatment of hypertensive persons sith kidney disease. Current Hipertension Reports 4: 191-194, 2002.
13. Macías JF, Fernández R, Calvo C, Grande J, Herrera J, Bustamante J y cols.: Verapamil reverts acute renal impairment induced by angiotensin II converting enzyme inhibitors. Ren Failure 25: 727-737, 2003.
14. Messerli FH: Calcium antagonists in hipertension: from hemodynamics to outcomes. Am J Hypertens 15 (Pt2): 94S-97S, 2002.
15. Neal B, MacMahon S, Chapman N: Effects of ACE inhibitors, calcium antagonists, and other bloodp-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 356: 1955-1964, 2000.
16. Opie LH, Schall R: Evidence-based evaluatium of calcium channel blocker for hipertension: equality of mortality and cardiovascular risk relative to conventional therapy. J Am Coll Cardiol 39: 315-322, 2002.
17. Rengo F, Romis L: Activity of lercanidipine in double-blind comparison with nitrendipine in combination treatment of patients with resistant essential hipertension. J Cardiovasc Pharmacol 29 (Supl. 2): S54-S58, 1997.
18. Morisco C, Trimarco B: Efficacy and tolerability of lercanidipine in comparison to and in combination with atenolol in patients with mild to moderate essential hipertension in a double blind controlled study. J Cardiovasc Pharmacol 29 (Supl. 2): S54-S58, 1997.
19. Barbagallo M, Barbagallo Sangiorgi G: Efficacy and tolerability of lercanidipine in monotherapy in elderly patients with isolated systolic hipertension. Aging Clin Exp Res 12: 375-379, 2000.
20. Messerli FH: Vasodilatory edema: a common side effect of antihypertensive therapy. Am J Hypertens 14: 978-979, 2001.
21. Hanson L, Lindholm LH, Ekbom T, Dahlöf B, Lanke J, Scherten B, Western P-O, Hedner T, Faire U: For the STOP-Hipertension-2 study group: randomized trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity. The Swedish Trial in Old Patients with Hipertension-2 Study. Lancet 354: 1751-1756, 1999.
22. Messerli FH, Oparil S, Feng Z: Comparison of efficacy and side effects of combination therapy of angiotensin-converting enzyme inhibitor (benazepril) with calcium antagonists (either nifedipine or amlodipine) versus high-dose calcium antagonists monotherapy for systemic hipertension. Am J Cardiol 86: 1182-1187, 2000.
23. Parving HH: The impact of hipertension and antihypertensive treatment on the course and prognosis of diabetic nephropathy. J Hypertens 8: S187-S191, 1990.
24. Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, King A, Klahr S, Massry SG, Seifter JL: Blood pressure control, proteinuria and the progression of renal disease: the Modification of Diet in Renal Disease Study. Ann Intern Med 123: 754-762, 1995.
25. Toto RD, Mitchell NC, Smith RD: «Strict» blood pressure control and progression of renal disease in hypertensive nephrosclerosis. Kidney Int 48: 851-859, 1995.
26. Gansevoort RT, Sluiter WJ, Hemmelder MH, De Zeeuw D, De Jong PE: Antiproteinuric effect of blood pressure lowering agents: a meta-analysis of comparative trials. Nephrol Dial Transplant 10: 1963-1974, 1995.
27. Maki DD, Ma JZ, Louis TA, Kasiske BL: Long-term effects of antihypertensive agents on proteinuria and renal function. Arch Intern Med 155: 1073-1080, 1995.
28. Weidmann P, Schneider M, Bohlen L: Therapeutic efficacy of different anti-hypertensive drugs in human diabetic nephropathy: an updated meta-analysis. Nephrol Dial Transplant 10 (Supl. 9): 39-45, 1995.
29. National High Blood Pressure Education Program Working Group on Hipertension and Renal Disease. 1995 Update of the working group reports on chronic renal failure and renovascular hipertension. Arch Intern Med 156: 1938-1947, 1996.
30. Voyaki SM, Staessen JA, Thijs L, Wang JG, Efstratopoulos AD, Birkenhäger WH, De Leeuw PW, Leonetti G, Nachev C, Rodicio JL, Tuomilehto J, Fagard R: For the Systolic Hipertension in Europe (Syst-Eur) Trial Investigators. Follow-up of renal function in treated and untreated older patients with isolated systolic hipertension. J Hypertens 19: 511-519, 2001.
31. Bakris GL, Mangrum A, Copley JB, Vicknair N, Sadler R: Effect of calcium channel or β-blockade on the progression of diabetic nephropathy in African Americans 29: 744-750, 1997.
32. Brown MJ, Palmer CR, Castaigne A, De Leeuw PW, Mancía G, Rosenthal T y cols.: Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Niefedipine GITS Study: intervention as a Goal in Hipertension Treatment (INSIGHT). Lancet 356: 366-372, 2000.
33. Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Brigs JP y cols.: Effect of ramipril vs amlodipine on renal otucomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 285: 2719-2728, 2001.
34. Praga M, Andrade CF, Luño J, Arias M, Poveda R, Mora J y cols.: Antiproteinuric efficacy of losartan in comparison with amlodipin in non-diabetic proteinuric renal diseases: a double-blind randomised clinical trial. Nephrol Dial Transplant 9: 1806-1813, 2003.
35. Robles NR, Vilatoro J, Pastor L, Manjón M, Ocón J, Gómez Campdera F, Herrera J, en nombre de los investigadores del estudio ZAFRA: Lercanidipino en pacientes con insuficiencia renal crónica. Nefrología 22 (Supl. 6): 33, 2002 (abstract).
36. Epstein M: Calcium antagonists and renal protection: emerging perspectives. J Hypertens 18 (Supl. 4): S17-S25, 1998.
37. Sabbatini M, Leonardi A, Testa R, Vitaioli L, Amenta F: Effect of calcium antagonists on glomerular arterioles in spontaneously hypertensive rats. Hipertension 35: 775-779, 2000.
38. Hebert LA, Bain RP, Verme D, Cattran D, Whittier FC, Tolchin N, Rohde RD, Lewis EJ, for the Collaborative Study Group: remission of nephrotic range proteinuria in type I diabetes. Kidney Int 46: 1688-1693, 1994.
39. Bakris GL, Williams B: ACE inhibitors and calcium antagonists alone or combined: is there a difference on progression of diabetic renal disease? J Hypertens 13 (Supl. 2): S95-S101, 1995.
40. Bakris GL, Weir MR, DeQuattro V, McMahon FG: Effects of an ACE inhibitor/calcium antagonists combination on proteinuria in diabetic nephropathy. Kidney Int 54: 1283-1289, 1998.
41. The effects of an ACE inhibitor and a calcium antagonists on the progression of renal disease: the Nephross Study. Nephrol Dial Transplant 16: 2158-2166, 2001.